Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines

C. De Santis, P. Robbioni, R. Longhi, L. Lopalco, A. G. Siccardi, A. Beretta, N. J. Roberts

Research output: Contribution to journalArticle

Abstract

Autoantibodies specific to HLA class I antigens were detected in the sera of persons vaccinated with human immunodeficiency virus type 1-derived recombinant vaccines by using synthetic peptides representing the amino acid sequences recognized by an HLA class I/gp120 cross-reactive monoclonal antibody. Study subjects received recombinant vaccinia gp160 (vacc-env) alone, vacc-env followed by one dose of recombinant gp160 (rgp160, 640 μg), or four doses of rgp160 alone (640 or 80 μg). All sera from vacc-env/rgp160- vaccinated subjects contained HLA/gp120 cross-reactive antibodies, as did all sera from recipients of the rgp160 alone at 640 μg/dose. In contrast, none of the sera from subjects who received either the vacc-env alone or the 80 μg/dose rgp160 alone contained detectable HLA cross-reactive antibodies, and these same sera showed little or no envelope reactivity on Western blot. The results showed a striking correlation between immunogenicity and the induction of cross-reactive antibodies by the rgp160 vaccine.

Original languageEnglish
Pages (from-to)1396-1403
Number of pages8
JournalJournal of Infectious Diseases
Volume168
Issue number6
Publication statusPublished - 1993

Fingerprint

HIV-1
Vaccines
Serum
Antibodies
Vaccinia
Histocompatibility Antigens Class I
Synthetic Vaccines
HLA Antigens
Autoantibodies
VaxSyn HIV-1 (gp160) vaccine
Amino Acid Sequence
Western Blotting
Monoclonal Antibodies
Peptides

ASJC Scopus subject areas

  • Immunology
  • Public Health, Environmental and Occupational Health

Cite this

Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines. / De Santis, C.; Robbioni, P.; Longhi, R.; Lopalco, L.; Siccardi, A. G.; Beretta, A.; Roberts, N. J.

In: Journal of Infectious Diseases, Vol. 168, No. 6, 1993, p. 1396-1403.

Research output: Contribution to journalArticle

De Santis, C. ; Robbioni, P. ; Longhi, R. ; Lopalco, L. ; Siccardi, A. G. ; Beretta, A. ; Roberts, N. J. / Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines. In: Journal of Infectious Diseases. 1993 ; Vol. 168, No. 6. pp. 1396-1403.
@article{794e46dbf715419fb14772eb4e935daa,
title = "Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines",
abstract = "Autoantibodies specific to HLA class I antigens were detected in the sera of persons vaccinated with human immunodeficiency virus type 1-derived recombinant vaccines by using synthetic peptides representing the amino acid sequences recognized by an HLA class I/gp120 cross-reactive monoclonal antibody. Study subjects received recombinant vaccinia gp160 (vacc-env) alone, vacc-env followed by one dose of recombinant gp160 (rgp160, 640 μg), or four doses of rgp160 alone (640 or 80 μg). All sera from vacc-env/rgp160- vaccinated subjects contained HLA/gp120 cross-reactive antibodies, as did all sera from recipients of the rgp160 alone at 640 μg/dose. In contrast, none of the sera from subjects who received either the vacc-env alone or the 80 μg/dose rgp160 alone contained detectable HLA cross-reactive antibodies, and these same sera showed little or no envelope reactivity on Western blot. The results showed a striking correlation between immunogenicity and the induction of cross-reactive antibodies by the rgp160 vaccine.",
author = "{De Santis}, C. and P. Robbioni and R. Longhi and L. Lopalco and Siccardi, {A. G.} and A. Beretta and Roberts, {N. J.}",
year = "1993",
language = "English",
volume = "168",
pages = "1396--1403",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines

AU - De Santis, C.

AU - Robbioni, P.

AU - Longhi, R.

AU - Lopalco, L.

AU - Siccardi, A. G.

AU - Beretta, A.

AU - Roberts, N. J.

PY - 1993

Y1 - 1993

N2 - Autoantibodies specific to HLA class I antigens were detected in the sera of persons vaccinated with human immunodeficiency virus type 1-derived recombinant vaccines by using synthetic peptides representing the amino acid sequences recognized by an HLA class I/gp120 cross-reactive monoclonal antibody. Study subjects received recombinant vaccinia gp160 (vacc-env) alone, vacc-env followed by one dose of recombinant gp160 (rgp160, 640 μg), or four doses of rgp160 alone (640 or 80 μg). All sera from vacc-env/rgp160- vaccinated subjects contained HLA/gp120 cross-reactive antibodies, as did all sera from recipients of the rgp160 alone at 640 μg/dose. In contrast, none of the sera from subjects who received either the vacc-env alone or the 80 μg/dose rgp160 alone contained detectable HLA cross-reactive antibodies, and these same sera showed little or no envelope reactivity on Western blot. The results showed a striking correlation between immunogenicity and the induction of cross-reactive antibodies by the rgp160 vaccine.

AB - Autoantibodies specific to HLA class I antigens were detected in the sera of persons vaccinated with human immunodeficiency virus type 1-derived recombinant vaccines by using synthetic peptides representing the amino acid sequences recognized by an HLA class I/gp120 cross-reactive monoclonal antibody. Study subjects received recombinant vaccinia gp160 (vacc-env) alone, vacc-env followed by one dose of recombinant gp160 (rgp160, 640 μg), or four doses of rgp160 alone (640 or 80 μg). All sera from vacc-env/rgp160- vaccinated subjects contained HLA/gp120 cross-reactive antibodies, as did all sera from recipients of the rgp160 alone at 640 μg/dose. In contrast, none of the sera from subjects who received either the vacc-env alone or the 80 μg/dose rgp160 alone contained detectable HLA cross-reactive antibodies, and these same sera showed little or no envelope reactivity on Western blot. The results showed a striking correlation between immunogenicity and the induction of cross-reactive antibodies by the rgp160 vaccine.

UR - http://www.scopus.com/inward/record.url?scp=0027515171&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027515171&partnerID=8YFLogxK

M3 - Article

C2 - 8245524

AN - SCOPUS:0027515171

VL - 168

SP - 1396

EP - 1403

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 6

ER -